Related Experiment Video

Updated: May 5, 2026

The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

27.2K

Decline in platelet count and long-term post-PCI ischemic events: implication of the intra-aortic balloon pump

Michele Schiariti1, Patrizia Saladini2, Domenico Cuturello3

  • 1Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, Sapienza University of Rome, Italy; Sant'Anna Hospital, Catanzaro, Italy.

Vascular Pharmacology
|November 19, 2013
PubMed

Insights

Thrombocytopenia (TC) after percutaneous coronary intervention (PCI) may not directly cause ischemic events. Intra-aortic balloon pump (IABP) use, however, is linked to worse outcomes in PCI patients with TC.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Hematology

Background:

  • Thrombocytopenia (TC) post-percutaneous coronary intervention (PCI) is linked to adverse hemorrhagic and ischemic outcomes.
  • Understanding the independent contribution of TC to ischemic events after PCI is crucial for patient management.

Purpose of the Study:

  • To re-examine the association between TC and ischemic events at 1-year follow-up post-PCI.
  • To investigate potential confounding factors, such as intra-aortic balloon pump (IABP) use, in the relationship between TC and ischemic outcomes.

Main Methods:

  • A real-world cohort of 861 patients undergoing PCI was analyzed.
  • Patients were categorized into groups with and without TC based on post-PCI platelet count changes.
  • Statistical models, including Cox regression, were used to assess the impact of TC and IABP on ischemic events.

Main Results:

  • Patients with TC exhibited a higher and earlier incidence of both hemorrhagic and ischemic events compared to those without TC.
  • Intra-aortic balloon pump (IABP) use was significantly higher (ten-fold) in patients with TC.
  • While TC was initially associated with ischemic outcomes, this association diminished after excluding patients who received IABP, suggesting IABP as a primary driver of adverse ischemic events.

Conclusions:

  • In patients undergoing PCI, intra-aortic balloon pump (IABP) use, rather than thrombocytopenia (TC) itself, appears to be a significant contributor to worse ischemic outcomes.
  • Further research is needed to elucidate the complex interplay between TC, IABP, and ischemic complications in the context of PCI.
Abstract

Keywords:
Ischemic eventsOutcomePCIPlatelet countThrombocytopenia

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

2.8K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
659
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
663
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
450